Cellectar Q2 2026 Results and Pipeline Update
Analysis based on 8 articles · First reported Jul 30, 2026 · Last updated Aug 13, 2026
The announcement of strong cash position and pipeline progress is likely to be viewed positively by investors, supporting the company's ability to fund operations into Q2 2027. However, the increased net loss and R&D spending may temper enthusiasm, and the stock's reaction will depend on perceived execution of upcoming milestones.
Cellectar Biosciences, a late-stage clinical biopharmaceutical company, announced its second quarter 2026 financial results and provided a corporate update on August 13, 2026. The company reported cash and cash equivalents of $34.0 million as of June 30, 2026, up from $13.2 million at the end of 2025, reflecting net proceeds of approximately $31.7 million from a May 2026 offering. R&D expenses increased to $4.6 million for the quarter, driven by the initiation of the WM confirmatory iopofosine I 131 and CLR 125 Triple Negative Breast Cancer studies. Net loss for the quarter was $6.9 million, or $0.57 per share. Key pipeline progress included initiation of site activation for the confirmatory Phase 3 study of iopofosine I 131 in Waldenström macroglobulinemia, with a New Drug Application submission planned for mid-2027 under the FDA's Accelerated Approval Program. The company also presented data from the CLOVER WaM trial at ASCO 2026, initiated enrollment and dosed first patients in the Phase 1b trial of CLR 125 in triple-negative breast cancer, and published Phase 1 data in the journal Cancers. Management expressed confidence in the company's momentum and near-term catalysts.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard